Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 4, 2017, Pages 466-475

  Wang, Fan ^a,b   Feng, Juerong ^a,b   Chen, Pengfei ^a,b,d   Liu, Xiaoping ^a   Ma, Minxing ^c   Zhou, Rui ^a,b   Chang, Ying ^a,b   Liu, Jing ^a,b   Li, Jin ^a,b   Zhao, Qiu ^a,b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases   (China)

^c the Fifth People's Hospital of Qinhai Province ^*  (China)

^d Central Hospital of Enshi Autonomous Prefecture   (China)

Author keywords

Eradication therapy; Helicobacter pylori; Network meta analysis; Probiotic

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ARTICLE; BAYES THEOREM; BIFIDOBACTERIUM; CLOSTRIDIUM BUTYRICUM; COMPARATIVE STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENTEROCOCCUS; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOCOCCUS LACTIS; META ANALYSIS; MORBIDITY; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; HELICOBACTER PYLORI; NETWORK META-ANALYSIS;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NETWORK META-ANALYSIS; PROBIOTICS;

EID: 85019856144     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2017.04.004     Document Type: Article

References (35)

1. Nagy, P., Johansson, S., Molloy-Bland, M., Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog, 8, 2016, 8.
2. Roberts, S.E., Morrison-Rees, S., Samuel, D.G., Thorne, K., Akbari, A., Williams, J.G., Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther 43:3 (2016), 334–345.
3. Sitas, F., Twenty five years since the first prospective study by Forman et al. (1991) on Helicobacter pylori and stomach cancer risk. Cancer Epidemiol 41 (2016), 159–164.
4. Potamitis, G.S., Axon, A.T., Helicobacter pylori and nonmalignant disease. Helicobacter Suppl. 1 (2015), 26–29.
5. Liou, J.M., Wu, M.S., Lin, J.T., Treatment of Helicobacter pylori infection – where we are now?. J Gastroenterol Hepatol, 2016, 10.1111/jgh.13418.
6. Liou, J.M., Chen, C.C., Lee, Y.C., Chang, C.Y., Wu, J.Y., Bair, M.J., et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 43:4 (2016), 470–481.
7. Hu, Y., Zhang, M., Lu, B., Dai, J., Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter, 2016, 10.1111/hel.12299.
8. Thung, I., Aramin, H., Vavinskaya, V., Gupta, S., Park, J.Y., Crowe, S.E., et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 43:4 (2016), 514–533.
9. Joint FAO/WHO Working Group. Report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, April 30 and May 1., 2002.
10. Gotteland, M., Brunser, O., Cruchet, S., Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?. Aliment Pharmacol Ther 23:8 (2006), 1077–1086.
11. Lee, J.S., Paek, N.S., Kwon, N.S., Hahm, K.B., Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism. Gastroenterol Hepatol 25:1 (2010), 194–202.
12. Lv, Z.F., Wang, B., Zhou, X.J., Wang, F., Xie, Y., Zheng, H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 9:3 (2015), 707–716.
13. Gong, Y., Li, Y., Sun, Q., Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 8:4 (2015), 6530–6543.
14. Li, B.Z., Threapleton, D.E., Wang, J.Y., Xu, J.M., Yuan, J.Q., Zhang, C., et al. Comparative effectiveness and tolerance of treatment for Helicobacter pylori: systematic review and network meta-analysis. BMJ, 351, 2015, h4052.
15. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17:1 (1996), 1–12.
16. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analysis. BMJ 327:7414 (2003), 557–560.
17. Mantel, N., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:4 (1959), 719–748.
18. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7:3 (1986), 177–188.
19. Dias, S., Welton, N.J., Caldwell, D.M., Ades, A.E., Checking consistency in mixed treatment comparison meta-analysis. Stat in Med 29:7–8 (2010), 932–944.
20. Dias, S., Sutton, A.J., Ades, A.E., Welton, N.J., Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33:5 (2013), 607–617.
21. Dias, S., Welton, N.J., Sutton, A.J., Caldwell, D.M., Lu, G., Ades, A.E., Inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:5 (2013), 641–656.
22. van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A.E., Welton, N.J., Automating network meta-analysis. Res Synth Methods 3:4 (2012), 285–299.
23. Spiegelhalter, D.J., Best, N.G., Carlin, B.P., van der Linde, A., Bayesian measures of model complexity and fit. J Roy Stat Soc 64:4 (2002), 583–639.
24. Wu, C., Chen, X., Liu, J., Li, M.Y., Zhang, Z.Q., Wang, Z.Q., Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter 16:2 (2011), 131–138.
25. Lu, C., Sang, J., He, H., Wan, X., Lin, Y., Li, L., et al. Probiotic supplementation dose not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep, 6, 2016, 23522.
26. Mukai, T., Asasaka, T., Sato, E., Mori, K., Matsumoto, M., Ohori, H., Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 32:2 (2002), 105–110.
27. Mukherjee, S., Ramesh, A., Bacteriocin-producing strains of Lactobacillus plantarum inhibit adhesion of Staphylococcus aureus to extracellular matrix: quantitative insight and implications antibacterial therapy. J Med Microbiol 64:12 (2015), 1514–1526.
28. Kim, T.S., Hur, J.W., Yu, M.A., Cheigh, C.I., Kim, K.N., Hwang, J.K., et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot 66:1 (2003), 3–12.
29. Khalil, M.A., EI-Sheekh, M.M., EI-Adawi, H.I., EI-Deeb, N.M., Hussein, M.Z., Efficacy of microencapsulated lactic acid bacteria in Helicobacter pylori eradication therapy. J Res Med Sci 20:10 (2015), 950–957.
30. Kim, J.E., Kim, M.S., Yoon, Y.S., Chung, M.J., Yum, D.Y., Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol 52:11 (2014), 955–962.
31. García, C.A., Henríquez, A.P., Retamal, R.C., Pineda, C.S., Delgado Sen, C., Gonzalez, C.C., Probiotic properties of Lactobacillus spp isolated from gastric biopsies of Helicobacter pylori infected and non-infected individuals. Rev Med Chil 137:3 (2009), 369–376.
32. Qin, Y.J., Chao, Y., Zhu, M.H., Compound capsule of lactobacillus combined triple therapy clinical observation on eradicating Helicobacter pylori infection. J Chin Pract Diagno Ther 27:6 (2013), 586–587.
33. Tan, X.L., Xie, C.H., Zhao, C., Chen, D.M., Efficacy of compound Lactobacillus combined with triple or quadruple therapy in eradicating Helicobacter pylori. Clin Med Eng 22:8 (2015), 1054–1055.
34. Xu, L., Xu, X.X., The Value of Probiotics in the treatment of refractory Helicobacter Pylori infection. Chin J Clin Gastroenterol 24:4 (2012), 218–219.
35. Cats, A., Kuipers, E.J., Boschaert, M.A., Pot, R.G., Vandenbroucke-Grauls, C.M., Kusters, J.G., Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 17:3 (2003), 429–435.